首页 | 本学科首页   官方微博 | 高级检索  
检索        

顺铂与紫杉醇不同给药方式治疗晚期卵巢癌的疗效对比分析
引用本文:吴超扬,郑崇广,马志红.顺铂与紫杉醇不同给药方式治疗晚期卵巢癌的疗效对比分析[J].国际医药卫生导报,2014,20(7):996-998.
作者姓名:吴超扬  郑崇广  马志红
作者单位:吴超扬 (529400,恩平市人民医院肿瘤科); 郑崇广 (529400,恩平市人民医院肿瘤科); 马志红 (529400,恩平市人民医院肿瘤科);
摘    要:目的 评价紫杉醇与顺铂不同给药方式治疗晚期卵巢癌的临床疗效.方法 选取2011年6月至2013年5月我院收治的100例晚期卵巢癌患者,随机分为两组,其中观察组50例,采用紫杉醇静脉滴注联合顺铂腹腔内给药治疗,对照组50例,采用紫杉醇联合顺铂静脉滴注给药,观察并比较两组患者的临床疗效及不良反应的发生率.结果 观察组有效率为84%,对照组有效率为56%,两组患者近期疗效相比较差异有统计学意义(P<0.05);在不良反应的发生上,白细胞减少程度相比较差异无统计学意义(P>0.05),但是观察组恶心呕吐、脱发、肾功能损害、肌肉关节痛的发生率明显低于对照组,差异有统计学意义(P<0.05).结论 紫杉醇静脉注射联合顺铂腹腔内给药治疗晚期卵巢癌疗效好,不良反应发生率低,值得在临床上予以推广.

关 键 词:紫杉醇  顺铂  卵巢癌  疗效

Comparative analysis of the efficacy of cisplatin and paclitaxel administered in different ways in the treatment of advanced ovarian cancer
Wu Chaoyang,Zheng Chongguang,Ma Zhihong.Comparative analysis of the efficacy of cisplatin and paclitaxel administered in different ways in the treatment of advanced ovarian cancer[J].International Medicine & Health Guidance News,2014,20(7):996-998.
Authors:Wu Chaoyang  Zheng Chongguang  Ma Zhihong
Institution:1.Department of Oncology, The People's Hospital of Enping City, Enping 529400, China;)
Abstract:Objective To evaluate the different modes of administration of paclitaxel and cisplatin in patients with advanced ovarian cancer.Methods From June 2011 to May 2013,100 cases of advanced ovarian cancer in our hospital were randomly divided into observation group and control group,50 cases in each group.Observation group used the intravenous infusion of paclitaxel plus cisplatin intraperitoneal treatment,while control group used paclitaxel and cisplatin administered intravenously.The clinical efficacy and the incidence of adverse reactions were observed and compared between two groups.Results The effective rate in observation group was 84%,while that in control group was 56%,with statistically significant difference in short-term efficacy between two groups (P < 0.05).The incidence of leukopenia had no statistically significant difference between two groups (P < 0.05).The incidences of nausea and vomiting,hair loss,kidney damage,muscle and joint pain in observation group were significantly lower than those in control group,with statistically significant differences (P < 0.05).Conclusion Intravenous administration of paclitaxel plus cisplatin intraperitoneal treatment of advanced ovarian cancer has good efficacy,with fewer adverse reactions,which should be promoted in clinical practice.
Keywords:Paclitaxel  Cisplatin  Ovarian cancer  Efficacy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号